Bevacizumab Does Not Improve Response, Survival in Ovarian Cancer

Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer.

Source: CancerNetwork - June 3, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Ovarian Cancer News Source Type: news